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Swedish National Diabetes Register (NDR) for 35,238 persons with type 2 diabetes
aged 30-74 years at diagnosis from January 1, 2004 to December 31, 2008 were
analyzed using the conditional non-frailty Weibull model. To not underestimate
the effect of BMI, two specifications of the model were estimated. Age at diagnosis,
sex, hypoglycaemic treatment, diabetes duration, microalbuminuria and smoking
were common covariates in both models.RESULTS:A total of 1409 patients had one
MI event and 200 experienced two events. The results showed that the risk of a
second MI differ from the risk of having a first MI. In addition, the effects of cova-
riates were not constant between multiple events. Women had a lower risk for
developing a first event compared to men, but a higher risk for a second event
conditional on the first MI. Preliminary results indicate four times higher hazard of
developing a MI conditional on a first MI during the follow up. CONCLUSIONS: The
findings show the need for an update of simulation models including health-eco-
nomic models and risk engines to include separate transition probabilities for first
and subsequent events for correct predictions of costs and quality of life gains.
Using recurrent event risk equations may reduce the bias from the previous as-
sumption of constant transition probabilities for consecutive events in health eco-
nomic models.
Cardiovascular Disorders – Cost Studies
PCV38
BUDGET IMPACT OF CHANGING FUTURE STATIN USE PATTERNS IN SWEDEN
Sternhufvud C1, Jacob J2, Costa-Scharplatz M3, Gandhi SK4
1AstraZeneca R&D, Mölndal, Sweden, 2AstraZeneca Nordic MC, Södertälje, Sweden,
3AstraZeneca R&D, Södertälje, Sweden, 4AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVES: To assess the health and budget impact of increasing use of rosuvas-
tatin in patients with high cardiovascular risk, while maintaining the overall level
of use, upon the entry of generic atorvastatin in Sweden. METHODS: A model was
developed to estimate the budget impact associated with changed statin utilization
pattern in different risk groups. The Framingham Risk equation was used to esti-
mate cardiovascular events, and the relative risk reduction for statins was modeled
using the JUPITER (Justification for the Use of statins in Primary prevention: an
Intervention Trial Evaluating Rosuvastatin) trial. A similar relative risk reduction
was used for primary and secondary prevention settings based on available liter-
ature. Baseline risk distribution was derived from the Malmö Primary Prevention
Study. The use of rosuvastatin was assumed to increase from 4% (2011) to 7% (2014)
in the high-risk group (27% baseline 10-year Framingham risk), but the overall use
was kept unchanged (4%). A gradual atorvastatin use increase was assumed with a
corresponding decrease in simvastatin use over 3 years. Cost calculations were
from Swedish public health sources. Generic price for atorvastatin was assumed to
be 5% of branded price. RESULTS: For the Swedish population on statin treatment
(810,304 patients, 25% with a previous history of CVD) the estimated budget impact
decreased by SEK 359 millions in 2012 (compared with 2011) and by SEK 441 mil-
lions in 2014 with changed statin utilization. The estimated number of CVD events
avoided ranged from 98 in 2012 to 197 in 2014 compared with current year (0.81%
decrease over the 3-year period). CONCLUSIONS: A shift to generic atorvastatin in
2012, accompanied by increased use of rosuvastatin in high-risk patients whilst
maintaining rosuvastatin overall use at current levels, was estimated to prevent
more cardiovascular events and resulted in overall healthcare budget savings for
the 3-year period in Sweden.
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OBJECTIVES: The antibody-mediated, prothrombotic heparin-induced thrombocy-
topenia type II (HIT-II) is a life-threatening disease with high thrombosis risk of
38-76% and up to 20% mortality. Pulmonary embolism occurs in up to 40% of pa-
tients, and amputations are necessary in up to 15%. The objective was to evaluate
frequency and cost of HIT-II in Germany. METHODS: Systematic literature
searches regarding epidemiology and cost of HIT-II were conducted until end of
2000 with Medical Subject Heading terms “incidence”, “epidemiology”, “risk”, and
“cost” each in combination with “heparin-induced thrombocytopenia”. German
secondary data were obtained by desktop research from the German Federal Sta-
tistical Office and a German university hospital. RESULTS: Literature search
yielded eleven relevant publications selected by successive title, abstract and
whole publication screening from a total of 1225 hits. Published incidence for HIT-II
in Germany was 0.039% for in-hospital patients, and average additional costs per
patient amounted to €9004 (Wilke et al., J Thromb Haemost, 2009). Data from the
German Federal Statistical Office for 2009 show an incidence of 0.05% for patients
with secondary diagnosis HIT-II, ICD-10 Code D69.53, corresponding to 8,585 cases
(age peak 65-85 years) with an average prolongation of hospital stay by 18 days. The
frequency of documented HIT-II as secondary diagnosis increased since 2005 by
60.4% (2005: 5353; 2006: 6263; 2007: 7177; 2008: 7454 cases). Estimated additional
costs generated by HIT-II in Germany in 2005 amount to 48 million euro, and in 2009
to a minimum of 77 million euro. CONCLUSIONS: Cost and burden of HIT-II are
considerable. Due to the demographic development to be expected in Germany
during the next decades in combination with the age peak of the disease a further
increase in HIT-II cases has to be anticipated. Data are limited. Further epidemio-
logical research and analysis of burden of disease from several perspectives are
needed.
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OBJECTIVES: To estimate the hospital impact with the introduction of vernakalant
in hospital emergency departments (EDs) in Spain.METHODS: Patients with recent
onset atrial fibrillation (AF) (48H) or non-permanent AF without thromboembolic
risk (anticoagulation or negative transesophageal echocardiography) were in-
cluded in the ED setting. Scenario: Data derived from the RHYTHM-AF-Spain study
or determined by the hospital. Budget impact model with the following variables:
percentage of use of anti-arrhythmic drugs (AAD) before and after the entry of
vernakalant, time to cardioversion with AAD and number of patients per year that
could be treated with vernakalant. Outcome variables: impact on pharmacy bud-
get, length of stay in ED (cost offset, additional patients treated in ED). Time to
achieve sinus rhythm for vernakalant, drug cost, and hospital stay were obtained
from published data. RESULTS: According to Spanish RHYTHM-AF study data, in
67% of these patients cardioversion (CV) is attempted with the following AAD (pro-
portion; mean time to normal sinus rhythm): amiodarone iv (55%; 7 hours), flecain-
ide iv/oral (12%/28%; 1.5/4.2 hours), propafenone iv/oral (1%/4%; 2/6.1 hours). It is
estimated that in a hospital like those enrolled in RHYTHM-AF, approximately 150
patients per year would be admitted into the ED and pharma-cardioversion would
be attempted in 101. Assuming that AADs were partially substituted for vernakal-
ant (30% for amiodarone, 15% flecainide oral, 5% flecainide iv, and 5% propafenone
oral), 22 patients would receive vernakalant per year. The annual incremental cost
is €7,772.13, but offset in 63.4% due to a reduction of 123.16 hours of stay in the ED
that would also allow for the assistance of 15 additional patients. CONCLUSIONS:
The reduction of hospital stay associated with the use of vernakalant carries a high
percentage of compensation costs associated with reduction of stay in the ED and
frees up resources to attend to more patients.
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OBJECTIVES: There has been enormous interest in the potential benefit, primarily
around decreased medical resource use, of the introduction of telehealth home
monitoring systems (THMS) for chronic disease management. Widespread adop-
tion has nevertheless been slow due to a lack of information on the financial im-
plications of implementation. THMS requires a substantial initial investment
which in a time of budget cuts needs economic justification. The objective of this
study was to provide an estimate of the potential short-term financial implications
of introducing the Care Innovations™ Guide THMS for patients with chronic heart
failure (CHF) in a typical PCT within the UK. METHODS: A one-year budget impact
model was developed looking at key financial drivers of CHF care including GP
visits, unplanned hospitalisation, ambulance time, etc. The model assessed the
impact on these costs after the introduction a THMS package for a PCT with a
population of 500,000, assuming the initial THMS uptake would be 30% of CHF
patients. Population and disease incidence and prevalence data for England were
taken from the Quality and Outcomes Framework 2009-10. Average costs per unit
of medical resource use, amount of resource use per year for a typical chronic CHF
patient receiving standard care and estimates of the impact of the THMS on re-
source use were estimated from published literature. RESULTS: The model esti-
mated that the introduction of THMS required an initial investment of £9,440,567
but yielded a return of 2% (£158,812) within one year. CONCLUSIONS: The intro-
duction of THMS requires considerable initial investment; however this model
suggests that this is offset within a very short time-frame due to reductions in
medical resource usage and is expected to lead to substantial savings over the
medium-term. This should encourage decision-makers to seriously consider mov-
ing from small pilot studies to more widespread implementation of THMS.
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OBJECTIVES:To assess the economic impact of adding SevikarHCT® to the Spanish
market for the treatment of arterial hypertension in the adult population aged over
35. SevikarHCT® concerns a new three-in-one combination tablet containing olm-
esartan medoxomil, amlodipine and hydrochlorothiazide. METHODS: To estimate
the economic impact a budget impact was developed using the Spanish national
healthcare system (NHS) perspective and a 3-year time horizon. The patient pop-
ulation was estimated based on disease prevalence, population growth and data on
the currently treated population with combinations of receptor blockers of the
antagonists of the angiotensin II (ARBII) with calcium channel blockers (CCB) alone
or together with diuretics (DIU) in fixed doses. Costs considered in this model
included drugs actually marketed or over the next three years consisting of Bal-
zak®, Balzak plus®, Capenon®, CapenonHCT®, Copalia®, CopaliaHCT®, Dafiro®,
DafiroHCT®, Exforge®, ExforgeHCT®, Imprida®, ImpridaHCT®, Twynsta®, Se-
vikar® and SevikarHCT® expressed in EUR 2010. Based on the annual drug costs
per patient and market shares for each treatment the economic burden before and
after the introduction of SevikarHCT® was estimated. A drop of 28% in drug prices
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